← Back to blog

Medical Device Market Access in the U.S.: A Practical Guide

November 13, 2026
Medical Device Market Access in the U.S.: A Practical Guide

Medical device market access is everything that happens between a regulatory decision and a device being used and paid for in real care: coverage, coding, payment, purchasing and clinician adoption. FDA clearance or approval is the entry ticket, not the finish line. For university teams and founders, the plan has to start years before submission, and the intellectual property behind the device has to be ready to carry it. This is how we at Tech Transfer Advisors help research teams think about it.

Techtransferadvisors
techtransferadvisors.com
Align IP Strategy With Market Access
Tech Transfer Advisors helps research teams shape intellectual property strategy and commercialization plans for medical devices and other innovations.
Visit

TL;DR

  • FDA authorization shows a device meets a regulatory bar. It does not mean Medicare or commercial payers will cover it, or that hospitals will buy it.
  • Classify the device first. Risk class (I, II or III) sets the pathway: exempt, 510(k), De Novo or PMA, and with it the evidence you must generate.
  • Reimbursement rests on three things: coding, coverage and payment. A missing code can block payment even when a payer is willing to cover.
  • Commercial payers often want more clinical evidence than FDA does, so design studies for both audiences from the start.
  • Clear IP ownership, a patent strategy and freedom to operate come before any of it. Investors and licensees check them first.

Table of Contents

What market access means (and what FDA authorization does not give you)

In the United States, a device can be legally marketed and still sell nothing. The FDA decides whether a device may be marketed. Payers decide whether to pay for it. Hospitals decide whether to buy it. Clinicians decide whether to use it. Each audience asks a different question and wants different proof.

The FDA's own vocabulary shows how narrow its role is. Under the 510(k) route, a manufacturer demonstrates substantial equivalence to a legally marketed device. "Approval" generally refers to PMA, the most stringent application, where the FDA requires sufficient valid scientific evidence of reasonable assurance that the device is safe and effective for its intended use. A cleared device and an approved device have been through different reviews, so use the terms precisely in grant applications, investor decks and licensing term sheets.

Downstream access is a separate hurdle. A Duke-Margolis Center for Health Policy paper notes that patient access to breakthrough devices depends on FDA approval, payer coverage decisions and physician adoption. It adds that FDA approval alone does not guarantee Medicare access.

For a researcher, the practical meaning is this: the evidence you generate in your lab and your first clinical studies will be read by regulators, payers and hospital buyers. Plan one evidence program that satisfies all three.

What market access means (and what FDA authorization does not give you)

Step 1: Classify your device and choose a pathway

Everything starts with risk classification. The FDA has classified about 1,700 generic device types into 16 medical specialty panels, and each is assigned to one of three classes based on the level of control needed to assure safety and effectiveness.

ClassRiskTypical routeExample of what FDA expects
ILowestGeneral controls; most are exempt from premarket notificationRegistration and listing may still apply
IIModerate510(k) clearance, or exemptSubstantial equivalence to a predicate
IIIHighestPremarket approval (PMA)Valid scientific evidence of reasonable assurance of safety and effectiveness

The FDA describes this risk-based, tiered approach with mechanical heart valves and implantable infusion pumps as examples of Class III devices. In a 510(k), the substantial equivalence decision is usually made within 90 days of submission, though a full timeline also includes preparation and any additional information requests.

What about a novel device with no suitable predicate and low to moderate risk? That is the De Novo pathway. If this sounds like your technology, our guide to the FDA De Novo pathway covers eligibility, process, fees and timeline.

The FDA frames the overall route in four steps: classify the device and understand its controls, select and prepare the right premarket submission, send it and interact with FDA staff during review, and comply with the applicable controls, including establishment registration and device listing. Where we help with this step is in matching the pathway to the commercial case, so the choice is made with the payer and investor in mind and not only the regulator. Our medical device regulatory strategy guide goes deeper.

Quality system rules now in force

The FDA's Quality Management System Regulation (QMSR) was issued on February 2, 2024, and took effect February 2, 2026. It incorporates ISO 13485:2016 by reference into 21 CFR Part 820 and applies to finished devices for human use. A spinout building its first design controls and documentation should build to that standard from day one, not retrofit it before a submission.

Step 2: Understand coverage, coding and payment

Reimbursement is where many academic devices stall. The NIH's Reimbursement Knowledge Guide for Medical Devices describes coverage, coding and payment as the building blocks of healthcare reimbursement:

  • Coding identifies the procedure or device for billing.
  • Coverage is a payer's decision to pay at all.
  • Payment is the amount actually transferred.

A missing or inadequate code can block payment even when a payer is otherwise willing to cover a technology. Check early whether an existing code fits your device or whether a new one is needed, because new codes take time.

Medicare

Medicare is run by the Centers for Medicare & Medicaid Services (CMS). According to the NIH guide, Medicare coverage requires that a device fall within at least one benefit category in Medicare law, not be specifically excluded by law, and be "reasonable and necessary." Coverage decisions come through national coverage determinations (NCDs) and local coverage determinations (LCDs). The Duke-Margolis paper explains that this is a different standard from FDA authorization: FDA approval and clinical evidence are inputs, not guarantees.

Commercial payers

Private plans have more flexibility than Medicare and Medicaid, which are subject to federal and state requirements. The NIH guide notes that commercial payers almost always require FDA approval before they approve coverage, and frequently require more evidence of clinical validity and clinical utility than FDA does. That has a direct design consequence: a pivotal study built only to satisfy the FDA may leave the payer's questions unanswered.

Evidence that outlasts the review

The same Duke-Margolis paper points out that Medicare beneficiaries are often underrepresented in clinical trials and that longer-term outcome data may not exist at approval. It argues that real-world evidence can support coverage that is more evidence-based, and that post-market evidence generation matters for the Medicare population. For a research team, this means budgeting for data collection after clearance, not just before it.

Step 3: Build the commercialization plan alongside the regulatory plan

Market access is a plan, not a phase. The pieces run in parallel:

  1. Customer need. Who buys, who uses and who pays? Hospital value-analysis committees, outpatient clinics and physician practices have different budgets. Our guide to biotech market research shows how to size and validate a market before you commit to a development path.
  2. Evidence. Map each stakeholder's evidence demand to a study or data source, and decide which one study can serve several.
  3. Quality and manufacturing. The design history file and device master record have to be in a state that a manufacturing team or contract manufacturer can build from. Early QMSR-compliant documentation makes that transfer smoother.
  4. Reimbursement. Identify the codes, the payers and the coverage route for your device.
  5. Distribution and adoption. Decide on direct sales, distributors or a strategic partner, and plan clinician training.
  6. Funding. Match each milestone to a funding source. Federal programs such as SBIR and STTR grants can pay for early validation without giving up equity.

How long does this take? Industry experience suggests that market access and reimbursement strategy can run to years of work, which is why the strategy belongs well before FDA submission. Our medical device commercialization roadmap lays out the sequence in more detail, and the broader life science commercialization guide covers the path from lab discovery to market.

Step 4: Secure the IP that every later step depends on

This is the part many academic teams underestimate, and it is the one most specific to universities. A device invented at a university with federal funding sits inside a legal framework. The Bayh-Dole Act is the legal framework for transferring federally funded university inventions to the commercial marketplace. In practice, the university's technology transfer office usually manages patenting and licensing, and a founder or outside company typically gets rights through a license or option.

Before you approach a payer, an investor or a clinical partner, settle these questions:

  • Ownership. Who owns the invention, and have all contributors assigned their rights?
  • Patent strategy. What is claimed, in which countries, and does it cover the product you will actually sell? Do not publish or present before filing.
  • Freedom to operate. Can you make and sell the device without infringing someone else's patents? Our guide explains how to run a freedom to operate analysis.
  • License terms. Exclusivity, field of use, milestones, royalties and sublicensing rights all affect how attractive a startup is to investors.
  • Diligence readiness. Investors and strategic acquirers will review the whole IP file. See what IP due diligence covers and how to prepare.

A weak IP position undermines every later step, because the device may be protected on paper but not in the market. Legal filings themselves are handled by patent counsel. Our team coordinates with a dedicated IP law partner, Silicon Slopes IP, so strategy and legal work stay aligned.

A worked example: a university-born Class II device

Imagine a biomedical engineering lab that has built a wearable sensor for monitoring a chronic condition. The path might look like this:

  1. Year 0. The inventors disclose to the tech transfer office. A patent filing is made before any conference talk. A freedom to operate review identifies one nearby patent family to design around.
  2. Year 1. The team forms a spinout and takes an exclusive license. An SBIR application funds prototype validation. The team confirms the device is Class II and identifies a predicate for a 510(k), or decides De Novo applies.
  3. Year 2. Design controls are built to the ISO 13485-based QMSR. A clinical study is designed so that its endpoints answer both FDA and a likely payer's questions.
  4. Year 3 onward. The 510(k) is filed. Coding and coverage work begins in parallel, not after clearance. Early hospital pilots generate real-world data for value analysis committees.

The numbers will differ by device. The point is the order: IP, evidence design and reimbursement planning all start before the regulatory submission, not after it.

Common mistakes that stall access

  • Treating clearance as the goal and starting reimbursement planning afterward.
  • Designing a study that satisfies FDA but ignores what payers need to see.
  • Letting IP ownership or license terms stay unresolved until a term sheet is on the table.
  • Choosing a pathway for speed alone, without considering how it affects coding and coverage.
  • Presenting "approved" and "cleared" as interchangeable in investor materials.

Our perspective

Researchers are trained to prove that something works. Market access asks a second question: who will pay for it, and what will they need to see? In our experience across university technology transfer offices, startup leadership, federal grant review and industry commercialization, the teams that move fastest answer that second question early.

That is why we treat IP strategy, licensing, regulatory direction, funding and go-to-market planning as one plan. A patent position shapes what investors will fund. A funding plan, including SBIR and STTR, shapes how much evidence you can afford to generate. The evidence you generate shapes your coverage story. Pulling these into a single sequence, with the investor and industry introductions that follow from it, is what our combined experience of more than 50 years is built to do.

If you are a university with a promising device, a researcher weighing a license, or a founder deciding where to spend the next dollar, start with the commercial question, then let it guide the regulatory and IP work.

the author

How Tech Transfer Advisors can help

We work with universities, researchers, founders and companies on IP and patent strategy, licensing agreement structuring, spinout formation, life sciences and medical device commercialization, go-to-market planning, investor introductions, and funding strategy including SBIR/STTR and other non-dilutive grants. Our team has worked inside major university technology transfer offices, in startup leadership, in federal grant review and in industry commercialization.

If your device is moving toward a submission and you want the IP, evidence and commercial plans lined up, see our consulting services.

Techtransferadvisors

For a broader view of how we work with research teams, visit Tech Transfer Advisors. If you are comparing support options for the regulatory side, our guide to FDA regulatory consulting explains what it covers and how to hire.

FAQ

Is FDA clearance the same as market access?

No. FDA clearance or approval means the device may be legally marketed in the United States. Market access also requires coding, payer coverage, payment, hospital purchasing and clinician adoption. Payers and Medicare use different standards from the FDA.

When should reimbursement planning start?

Before you submit to the FDA, ideally during device design and study planning. Commercial payers frequently want clinical validity and utility evidence beyond what FDA requires, according to the NIH reimbursement guide, so the study design should reflect that from the start.

What is the difference between 510(k), De Novo and PMA?

A 510(k) shows substantial equivalence to a legally marketed predicate. De Novo is for novel low to moderate risk devices with no suitable predicate. PMA is for the highest-risk Class III devices and requires valid scientific evidence of safety and effectiveness. The FDA's overview of device pathways lists each one.

Can a university researcher commercialize a device invented with federal funding?

Yes, usually through the university's technology transfer office, which manages patenting and licensing under the framework of the Bayh-Dole Act. The inventor or a new spinout typically obtains rights through a license, so ownership and license terms should be settled early.

Do all devices need a premarket submission?

No. Many low-risk Class I devices are exempt from premarket notification, although registration and listing may still apply. Confirm the classification of your specific device before assuming an exemption.

Sources